[
    [
        {
            "time": "2020-12-09",
            "original_text": "新冠疫苗是航空股“救命药”？业内：板块回暖仍待需求恢复",
            "features": {
                "keywords": [
                    "新冠疫苗",
                    "航空股",
                    "救命药",
                    "板块回暖",
                    "需求恢复"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "航空"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "新冠疫苗是航空股“救命药”？业内：板块回暖仍待需求恢复",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "金域医学：君睿祺、君联茂林合计减持1.4514%公司股份 减持股份",
            "features": {
                "keywords": [
                    "金域医学",
                    "君睿祺",
                    "君联茂林",
                    "减持"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "金域医学：君睿祺、君联茂林合计减持1.4514%公司股份 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "金域医学(603882.SH)：君睿祺及君联茂林减持期届满合计减持666.92万股 减持股份",
            "features": {
                "keywords": [
                    "金域医学",
                    "君睿祺",
                    "君联茂林",
                    "减持期届满",
                    "减持"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "金域医学(603882.SH)：君睿祺及君联茂林减持期届满合计减持666.92万股 减持股份",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "医药生物2021年投资策略报告：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "报告"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物2021年投资策略报告：不畏浮云遮望眼",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
            "features": {
                "keywords": [
                    "医药",
                    "白酒",
                    "2021年度策略",
                    "次新股",
                    "圣农发展"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "白酒"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "晨报1209 | 医药&白酒2021年度策略、次新股专题、圣农发展（002299）",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "国内财经媒体头版2020年12月9日星期三",
            "features": {
                "keywords": [],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国内财经媒体头版2020年12月9日星期三",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2020-12-09",
            "original_text": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药生物",
                    "投资策略",
                    "展望"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "中信建投2021年医药生物投资策略展望：不畏浮云遮望眼",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]